Park Place Capital Corp Sells 1,062 Shares of AstraZeneca PLC (NASDAQ:AZN)

Park Place Capital Corp trimmed its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 29.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,580 shares of the company’s stock after selling 1,062 shares during the quarter. Park Place Capital Corp’s holdings in AstraZeneca were worth $169,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. McClarren Financial Advisors Inc. grew its stake in shares of AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after purchasing an additional 247 shares during the last quarter. Capital Performance Advisors LLP bought a new stake in shares of AstraZeneca in the 3rd quarter valued at about $28,000. Albion Financial Group UT increased its stake in shares of AstraZeneca by 68.9% in the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after buying an additional 248 shares during the period. Groupama Asset Managment raised its position in shares of AstraZeneca by 22.9% during the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after acquiring an additional 101,225 shares during the last quarter. Finally, Ashton Thomas Securities LLC acquired a new position in shares of AstraZeneca in the third quarter worth approximately $45,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Up 0.4 %

Shares of NASDAQ AZN opened at $68.20 on Thursday. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The firm has a market cap of $211.49 billion, a PE ratio of 32.63, a P/E/G ratio of 1.13 and a beta of 0.46. The company’s fifty day simple moving average is $66.20 and its 200 day simple moving average is $74.32. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the prior year, the firm earned $0.87 EPS. The business’s revenue was up 18.0% on a year-over-year basis. As a group, sell-side analysts forecast that AstraZeneca PLC will post 4.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, AstraZeneca has an average rating of “Buy” and a consensus target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.